Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma

Junfeng Liu,Xi Li,Jiawen Chen,Jingpei Guo,Hui Guo,Xiaoting Zhang,Jinming Fan,Ke Zhang,Junjie Mao,Bin Zhou

DOI: https://doi.org/10.1186/s12951-024-02579-1

IF: 10.2

2024-06-19

Journal of Nanobiotechnology

Abstract:Incomplete radiofrequency ablation (iRFA) in hepatocellular carcinoma (HCC) often leads to local recurrence and distant metastasis of the residual tumor. This is closely linked to the development of a tumor immunosuppressive environment (TIME). In this study, underlying mechanisms and potential therapeutic targets involved in the formation of TIME in residual tumors following iRFA were explored. Then, TAK-981-loaded nanocomposite hydrogel was constructed, and its therapeutic effects on residual tumors were investigated.

biotechnology & applied microbiology,nanoscience & nanotechnology

What problem does this paper attempt to address?

The paper attempts to address the issue of local recurrence and distant metastasis caused by residual tumors after radiofrequency ablation (RFA) treatment in hepatocellular carcinoma (HCC). Specifically, the study focuses on the mechanisms of tumor immune suppressive microenvironment (TIME) formation induced by incomplete radiofrequency ablation (iRFA) and its potential therapeutic targets. The researchers explored the mechanisms related to the formation of TIME in residual tumors after iRFA and developed a nano-composite hydrogel loaded with TAK-981 to optimize the RFA treatment effect and reduce the development of residual tumors. By inhibiting the SUMOylation pathway, the study demonstrated the potential of this novel therapeutic approach in activating anti-tumor immune responses and inhibiting residual tumor growth, and proposed the possibility of combining it with PD-L1 blockade therapy to further enhance therapeutic efficacy.